Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BMS-906024 |
Synonyms | |
Therapy Description |
BMS-906024 is a pan-NOTCH inhibitor, which may limit growth and survival of cancer cells (PMID: 28978720). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMS-906024 | AL 101|AL101|AL-101 | NOTCH Inhibitor (Pan) 5 | BMS-906024 is a pan-NOTCH inhibitor, which may limit growth and survival of cancer cells (PMID: 28978720). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
APC inact mut | desmoid tumor | predicted - sensitive | BMS-906024 | Case Reports/Case Series | Actionable | In a clinical case study, BMS-906024 treatment resulted in a partial response that lasted for at least 2.6 years in a patient with a desmoid tumor harboring an inactivating APC mutation (PMID: 34590610). | 34590610 |
CTNNB1 T41A | desmoid tumor | predicted - sensitive | BMS-906024 | Case Reports/Case Series | Actionable | In a Phase I trial, BMS-906024 treatment resulted in a partial response that lasted for 3.6 years on treatment and at least another 4 years after the end of treatment in a patient with a desmoid tumor harboring CTNNB1 T41A (PMID: 34590610; NCT01292655). | 34590610 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04973683 | Phase I | BMS-906024 | AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer | Active, not recruiting | USA | 0 |
NCT01292655 | Phase I | BMS-906024 | Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | CAN | AUS | 0 |
NCT01653470 | Phase I | Carboplatin Fluorouracil + Irinotecan + Leucovorin BMS-906024 Paclitaxel | Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors | Completed | USA | CAN | BEL | 0 |
NCT03691207 | Phase II | BMS-906024 | A Study Of AL101 In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations (ACCURACY) | Completed | USA | NLD | ISR | GBR | FRA | CAN | 0 |
NCT01363817 | Phase I | Dexamethasone BMS-906024 | Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | Completed | USA | FRA | DEU | 0 |
NCT04461600 | Phase II | BMS-906024 | A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer (TENACITY) | Terminated | USA | ISR | GBR | ESP | BEL | 0 |